COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis.
Front Immunol
; 11: 2086, 2020.
Artículo
en Inglés
| MEDLINE | ID: covidwho-771524
ABSTRACT
Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Síndrome de Churg-Strauss
/
Granulomatosis con Poliangitis
/
Infecciones por Coronavirus
/
Ciclofosfamida
/
Betacoronavirus
/
Inmunosupresores
Tipo de estudio:
Reporte de caso
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Adulto
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Front Immunol
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Fimmu.2020.02086
Similares
MEDLINE
...
LILACS
LIS